[Close]
This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Zofin

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Zofin or Organicell Flow is an unapproved treatment that has been used on a number of patients severely ill with long-lasting COVID-19 symptoms under a compassionate use authorization.[1][2] Zofin is a biological product derived from the human amniotic fluid (HAF) donated from the births of healthy, newborn babies; it is administered by intravenous infusion.

Zofin is produced by the company Organicell which states that it "contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells" including the proteins CD63, CD81, and CD9 in addition to high expression of CD133.[1]

Theory[edit | edit source]

According to Organicell, pro-inflammatory cytokines believed to be targeted by Zofin include tumor necrosis factor (TNF), IL-6, and IL-8, and published research states that targeting these may "reduce the severity of symptoms associated with elevated immune response".[1]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Zofin has not yet been approved for use and clinical trials remain ongoing.[3]

Risks, side effects and safety are largely unknown.

Costs and availability[edit | edit source]

Zofin is not yet an approved drug and availability is limited to special authorizations.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ Jump up to: 1.0 1.1 1.2 Organicell (May 27, 2020). "Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients". Retrieved December 13, 2020.
  2. ↑ Caldwell, Blair (November 23, 2020). "Savannah doctor providing treatment for long-term COVID-19 effects". WTOC. Retrieved December 13, 2020.
  3. ↑ https://clinicaltrials.gov/ct2/show/NCT04384445

extracellular vesicle An extracellular vesicle (sometimes abbreviated EV) is a piece of a cell that has broken off and formed a separate membrane-bound vesicle. A membrane-bound vesicle is like a bubble, or like a mini-cell, in that it has a membrane surrounding some liquid. An extracellular vesicle may also contain some parts of the cell from which the extracellular vesicle arose. There are currently two types of extracellular vesicles: "exosomes" and "microvesicles". An "exosome" is an extracellular vesicle that began inside the cell as an intracellular vesicle known as an "endosome". A "microvesicle" is an extracellular vesicle that begins at the cell surface, and pinches off the cell's own membrane to form a separate vesicle. (Learn more: journals.physiology.org)

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

adverse reaction Any unintended or unwanted response to a treatment, whether in a clinical trial or licensed treatment. May be minor or serious.

Retrieved from "https://me-pedia.org/w/index.php?title=Zofin&oldid=239131"